LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
and commercialization of innovative and effective therapeutics for
the treatment of cancer, today announced that the Company will
release its second quarter 2018 financial results
on Thursday, August 2, 2018, before the U.S. financial markets
open. The Company's management will also host a conference call on
the same day at 8:30 a.m. EDT.
To access the live conference call, please dial (888) 346-6389
from the United States or 1 (412)
317-5252 from other locations, shortly before 8:30 a.m. EDT. The conference call can also be
accessed on the Curis website at www.curis.com in the Investors
section. A replay of the financial results conference call will be
available on the Curis website shortly after completion of the
call.
About Curis, Inc.
Curis is a biotechnology company focused on the development and
commercialization of innovative therapeutics for the treatment of
cancer, including fimepinostat, which is being investigated in
clinical studies in patients with DLBCL and solid
tumors. Curis is also engaged in a collaboration with Aurigene
in the areas of immuno-oncology and precision oncology. As
part of this collaboration, Curis has exclusive licenses to oral
small molecule antagonists of immune checkpoints including, the
PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327,
as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is
currently undergoing testing in a Phase 1 trial in patients with
advanced solid tumors and lymphomas, and in a Phase 2 trial
in India conducted by Aurigene. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with non-Hodgkin
lymphoma. Curis is also party to a collaboration with Genentech, a
member of the Roche Group, under which Genentech and Roche are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website
at www.curis.com.
View original
content:http://www.prnewswire.com/news-releases/curis-to-release-second-quarter-financial-results-and-hold-conference-call-on-august-2-2018-300687660.html
SOURCE Curis, Inc.